JP-CSPC@EC2602C(19427.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
JP-CSPC@EC2602C
19427.HK
News
View More

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50.

Tip Ranks·
SZ
300765
-7.59%
HK
01093
-4.69%
SH
562050
-2.79%
Tip Ranks·
SZ
300765
-7.59%
HK
01093
-4.69%
SH
562050
-2.79%

CSPC Pharmaceutical Group Receives Approval for Clevidipine Injectable Emulsion

CSPC Pharmaceutical Group Limited has received drug registration approval from China's National Medical Products Administration for its Clevidipine Injectable Emulsion, indicated for hypertension treatment when oral therapy is not feasible. The product offers rapid action, requires no dose adjustment for hepatic or renal dysfunction, and can be administered without dilution, making it suitable for patients at risk of fluid overload. This approval is expected to enhance the company's cardiovascular product pipeline.

Reuters·
SH
562050
-2.79%
HK
01093
-4.69%
SH
510660
-2.47%
Reuters·
SH
562050
-2.79%
HK
01093
-4.69%
SH
510660
-2.47%

AstraZeneca escalates Big Pharma’s China land grab

AstraZeneca has entered a licensing agreement with China's CSPC Pharmaceutical for weight-loss drugs, valued at up to $18.5 billion. The UK-based company will pay $1.2 billion upfront and potentially $17.3 billion more based on milestones. Additionally, AstraZeneca plans to invest $15 billion in China over the next five years for manufacturing and R&D. Following the announcement, CSPC's shares dropped 10.2%, while AstraZeneca's stock rose 1%.

Reuters·
US
AZN
+1.94%
SZ
300765
-7.59%
HK
01093
-4.69%
Reuters·
US
AZN
+1.94%
SZ
300765
-7.59%
HK
01093
-4.69%

In "The Big Firms," China International Capital Corporation raised the target price for CSPC PHARMA to 12 yuan, expecting to continue achieving external licensing implementation

CICC raised the target price of CSPC PHARMA to HKD 12, expecting the company to continue achieving external licensing agreements. CSPC PHARMA has reached a collaboration with AstraZeneca, authorizing it to develop 8 innovative drug projects globally, with AstraZeneca paying a USD 1.2 billion upfront payment and subsequent milestone payments. CICC maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.353 billion, respectively, and introduces a forecast for 2027 at RMB 5.695 billion

AASTOCKS·
SH
562050
-2.79%
HK
01093
-4.69%
SH
510660
-2.47%
AASTOCKS·
SH
562050
-2.79%
HK
01093
-4.69%
SH
510660
-2.47%

CICC Sticks to Its Buy Rating for CSPC Pharmaceutical Group (CHJTF)

CICC has reaffirmed its Buy rating for CSPC Pharmaceutical Group (CHJTF) with a price target of HK$12.00. Additionally, TipRanks also issued a Buy rating for the company. However, on the same day, TipRanks downgraded CSPC Pharmaceutical Group to a Hold.

Tip Ranks·
HK
01093
-4.69%
Tip Ranks·
HK
01093
-4.69%
Posts
View More
© 2026 Longbridge｜Disclaimer